Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts

BMC Medicine

Raymond Hutubessy³  Jane Kim¹  Johannes Berkhof⁵  Stephen Resch¹  Ann Levin⁶  Marc Brisson⁴  Carol Levin²  Mark Jit⁷ 

[1] Center for Health Decision Science, Harvard School of Public Health, 718 Huntington Ave, Boston, MA 02130, USA;PATH, 2201 Westlake Avenue, Suite 200 Seattle, WA 98121 USA;Initiative for Vaccine Research, World Health Organization, 20 Avenue Appia, CH-1211 Geneva, Switzerland;Department of Infectious Disease Epidemiology, Imperial College, London, UK;Department of Epidemiology and Biostatistics, VU University Medical Centre, PO box 7057, 1007 MB Amsterdam, The Netherlands;Independent Consultant, 6414 Hollins Dr., Bethesda, MD 20817 USA;Modelling and Economics Unit, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK

关键词: economic evaluation.;    low- and middle-income countries;    vaccination;    Human papillomavirus;   

Others  :  857211
DOI  :  10.1186/1741-7015-11-23

 received in 2012-11-02, accepted in 2013-01-30,  发布年份 2013

【 摘 要 】

Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. Analysts informing policy decisions should address the following questions: 1) Is an economic analysis needed? 2) Should analyses address costs, epidemiological outcomes, or both? 3) If costs are considered, what sort of analysis is needed? 4) If outcomes are considered, what sort of model should be used? 5) How complex should the analysis be? 6) How should uncertainty be captured? 7) How should model results be communicated? Selecting the appropriate analysis is essential to ensure that all the important features of the decision problem are correctly represented, but that the analyses are not more complex than necessary. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries.

【 授权许可】

   
2013 Jit et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]World Health Organization: Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009, 84:118-131.
• [2]Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach J: Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med 2011, 9:55. BioMed Central Full Text
• [3]Yothasamut J, Tantivess S, Teerawattananon Y: Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable? Value Health 2009, 12(Suppl 3):S26-S30.
• [4]Andrus JK, Toscano CM, Lewis M, Oliveira L, Ropero AM, Davila M, Fitzsimmons JW: A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Rep 2007, 122:811-816.
• [5]Iglesias CP, Drummond MF, Rovira J: Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. Int J Technol Assess Health Care 2005, 21:1-14.
• [6]Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R: Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med 2011, 9:54. BioMed Central Full Text
• [7]Kim JJ, Brisson M, Edmunds WJ, Goldie SJ: Modeling cervical cancer prevention in developed countries. Vaccine 2008, 26(Suppl 10):K76-K86.
• [8]Brisson M, Van d V, Boily MC: Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351.
• [9]Levin CE, Van Minh H, Odaga J, Sarit Rout S, Nguyen Thi Ngoc D, Menezes L, Mendoza Araujo M, La Montagne DS: Incremental costs of strategies to deliver human papillomavirus vaccine to young adolescent girls in India, Peru, Uganda and Viet Nam. Bull World Health Organ 2012, in press.
• [10]Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY: Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26:4080-4093.
• [11]Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
• [12]Walker DG, Hutubessy R, Beutels P: WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28:2356-2359.
• [13]Tracy L, Gaff HD, Burgess C, Sow S, Gravitt PE, Tracy JK: Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali. Clin Infect Dis 2011, 52:641-645.
• [14]Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A', Chichareon S, Ieumwananonthachai N, Tangcharoensathien V: Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics 2011, 29:781-806.
• [15]Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C: Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis. Vaccine 2009, 27:6060-6079.
• [16]Kim JJ, Andres-Beck B, Goldie SJ: The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97:1322-1328.
• [17]Senouci K, Blau J, Nyambat B, Coumba FP, Gautier L, Da Silva A, Favorov MO, Clemens JD, Stoeckel P, Gessner BD: The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) initiative: a country-driven, multi-partner program to support evidence-based decision making. Vaccine 2010, 28(Suppl 1):A26-A30.
• [18]Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P: Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health 2007, 10:336-347.
• [19]Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJLe: Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organisation; 2003. Geneva, World Health Organisation; 2003.
• [20]Van d V, Brisson M, Boily MC: Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010, 28:5473-5484.
• [21]Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J: Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011, 22:505-515.
• [22]Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.
• [23]Dee A, Howell F: A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010, 20:213-219.
• [24]Brisson M, Van d V, De Wals P, Boily MC: The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25:5399-5408.
• [25]Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M: Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012.
• [26]Brennan A, Chick SE, Davies R: A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006, 15:1295-1310.
• [27]Wellings K, Nanchahal K, Macdowall W, McManus S, Erens B, Mercer CH, Johnson AM, Copas AJ, Korovessis C, Fenton KA, et al.: Sexual behaviour in Britain: early heterosexual experience. Lancet 2001, 358:1843-1850.
• [28]Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJ, Berkhof J, Wallinga J: Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 2011, 8:e1001147.
• [29]Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J: The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009, 27:6196-6202.
• [30]Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290:781-789.
• [31]health-economic Modelling of Prevention STrategies for Hpv-related Diseases in European Countries [http:/ / cordis.europa.eu/ search/ index.cfm?fuseaction=proj.document& PJ_RCN=11314364] webcite Accessed on 29 November 2012
• [32]Lasry A, Richter A, Lutscher F: Recommendations for increasing the use of HIV/AIDS resource allocation models. BMC Public Health 2009, 9(Suppl 1):S8. BioMed Central Full Text
• [33]Bilcke J, Beutels P, Brisson M, Jit M: Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011, 31:675-692.
• [34]Claxton K: The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999, 18:341-364.
• [35]Craig BM, Brisson M, Chesson H, Giuliano AR, Jit M: Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmo, Sweden, May 9-10, 2009. Clin Ther 2010, 32:1546-1564.